Elotuzumab, Lenalidomide, and Dexamethasone as Salvage Therapy for Multiple Myeloma
Prior therapy with lenalidomide and shorter disease history were found to correlate with poorer outcomes.
Prior therapy with lenalidomide and shorter disease history were found to correlate with poorer outcomes.
Patients who received hydroxycarbamide therapy scored higher on several measures of neurocognition compared to patients who did not receive hydroxycarbamide.
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.
A 3-cycle Plan-Do-Study-Act intervention resulted in increased nurse and physician education on mucositis and a nurse-driven protocol that reduced MBI-LCBIs by 25%.
Although 76% of patients reported experiencing complications during treatment, the mortality rate per episode was only 3.7%.
Patients with acute myeloid leukemia with myelodysplasia-related changes diagnosed on the basis of dysplasia reported improved overall and event-free survival.
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Neither factor VIII clotting activity nor factor VIII antigens were significantly different for any blood group in patients with nonsevere hemophilia A.
In the extension study, 53% of patients receiving ropeginterferon alfa-2b met the primary end points, compared with 38% of patients receiving hydroxyurea.